Physician profile
David Denholm
NPI 1699763870
$7,526.82
in general payments reported to CMS, 2019-2025
35 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,310 · 2020: $1,262 · 2021: $1,977 · 2022: $2,218 · 2023: $209 · 2024: $312 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $759.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,377.45 | 2019-2024 | Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $1,137.42 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $910.53 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $479.54 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $437.75 | 2020-2024 | Cuvitru |
| Grifols USA, LLC | $413.19 | 2019-2024 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $385.22 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $205.63 | 2019-2022 | |
| Mylan Specialty L.P. | $199.26 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $186.76 | 2019-2022 | |
| Genzyme Corporation | $177.39 | 2021-2025 | |
| United Therapeutics Corporation | $149.40 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $148.00 | 2019-2022 | |
| Harmony Biosciences LLC | $143.49 | 2020-2021 | |
| Insmed, INC. | $133.84 | 2019-2025 | Arikayce |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $113.50 | 2019 | |
| Paratek Pharmaceuticals, INC. | $111.51 | 2020-2022 | |
| Inogen, INC. | $110.49 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Electromed, INC. | $102.38 | 2021-2023 | Smartvest |
| Shionogi INC | $83.28 | 2021-2022 | |
| Advanced Respiratory, INC | $68.58 | 2019-2021 | |
| Genentech USA, INC. | $64.68 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $60.84 | 2020-2022 | |
| Inspire Medical Systems, INC. | $43.16 | 2023 | Inspire |
| Amgen INC. | $42.75 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $39.01 | 2019-2021 | |
| Pfizer INC. | $35.14 | 2019-2020 | |
| Shire North American Group INC | $32.12 | 2019 | |
| Baxter Healthcare | $25.08 | 2022 | |
| Nabriva Therapeutics, Plc | $21.49 | 2022 | |
| Merck Sharp & Dohme LLC | $21.21 | 2022 | |
| Resmed Corp | $19.51 | 2022 | |
| Gilead Sciences, INC. | $18.17 | 2024 | Veklury |
| Sandoz INC. | $17.45 | 2022 | |
| Circassia INC. | $11.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Denholm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.